^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
PANDA-VAC
i
Other names: PANDA-VAC, Personalized and adaptive neoantigen dose-adjusted vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
UNC Lineberger Comprehensive Cancer Center
Drug class:
Immunostimulant
Related drugs:
16d
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
P1, N=6, Suspended, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Suspended | Trial primary completion date: Jun 2026 --> Jun 2027
Trial suspension • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • PANDA-VAC
over1year
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Trial primary completion date: Jun 2025 --> Jun 2026
Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • PANDA-VAC
2years
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Trial primary completion date: Jun 2024 --> Jun 2025
Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • PANDA-VAC
almost3years
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Trial primary completion date: Jun 2023 --> Jun 2024
Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • PANDA-VAC
almost4years
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Oct 2032 --> Jun 2033 | Trial primary completion date: Oct 2022 --> Jun 2023
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • PANDA-VAC
almost5years
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Apr 2031 --> Oct 2032 | Trial primary completion date: Apr 2021 --> Oct 2022
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • PANDA-VAC
6years
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center | Initiation date: Feb 2020 --> Sep 2020
Trial initiation date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • PANDA-VAC
6years
PANDA-VAC: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (clinicaltrials.gov)
P1, N=6, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
New P1 trial
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • PANDA-VAC
Share via
